Outcome measures for Psoriasis severity: A report from the GRAPPA 2012 annual meeting

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1423-1424

  Duffin, Kristina Callis ^a   Gottlieb, Alice B ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

OMERACT; Outcome measures; Physician global assessment; Psoriasis; Psoriatic arthritis

Indexed keywords

CONFERENCE PAPER; DISEASE SEVERITY; ERYTHEMA; HUMAN; LATTICE SYSTEM PHYSICIAN GLOBAL ASSESSMENT; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS OUTCOME MEASURES; SCORING SYSTEM; SKIN INDURATION; SWEDEN;

OMERACT; OUTCOME MEASURES; PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS;

ARTHRITIS, PSORIATIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 84881447933     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130454     Document Type: Conference Paper

References (10)

1. Gladman DD, Helliwell PS, Khraishi M, Callis Duffin K, Mease PJ. Dermatology screening tools: Project update from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1425-7.
2. Gottlieb AB, Armstrong AW. Psoriasis outcome measures: A report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1428-33.
3. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933-43.
4. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
5. Naldi L, Svensson A, Zenoni D, Diepgen T, Elsner P, Grob JJ, et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: Update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol 2010;162:384-9.
6. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75.
7. Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting 1998: Food and Drug Administration, Department of Health and Human Services, Public Health Service, March 20, 1998. Washington, DC: Miller Reporting Company, Inc; 1998.
8. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
9. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
10. OMERACT-International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. [updated 2013; cited 18 March 2013]; Available from: www.omeract.org